Title:A Novel Oncogenic Role of Disulfidptosis-related Gene SLC7A11 in
Anti-tumor Immunotherapy Response to Human Cancers
Volume: 24
Issue: 8
Author(s): Borui Xu, Jiahua Liang, Liangmin Fu, Jinhuan Wei*Juan Lin*
Affiliation:
- Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University,
Guangzhou, 510080, People's Republic of China
- Department of Pediatrics, Third Affiliated Hospital,
Sun Yat-Sen University, Guangzhou, 510630, People's Republic of China
Keywords:
Solute carrier family 7 member 11, pan-cancer, prognostic biomarker, tumor microenvironment, hepatocellular carcinoma, cancer therapy.
Abstract:
Background: The protein Solute Carrier Family 7 Member 11 (SLC7A11) plays a pivotal
role in cellular redox homeostasis by suppressing disulfidptosis, which restricts tumor growth.
Yet, its relevance in prognosis, immunity, and cancer treatment efficacy is not well understood.
Methods: We conducted a comprehensive analysis of the expression of SLC7A11 across 33 cancer
types, employing datasets from public databases. Methods, such as Cox regression and survival
analyses assessed its prognostic significance, while functional enrichment explored the biological
processes tied to SLC7A11. The association between SLC7A11 expression, immune cell infiltration,
and immune-related gene expression was also scrutinized.
Results: Notably, SLC7A11 expression was more pronounced in cancerous compared to normal
samples and correlated with higher tumor grades. Increased SLC7A11 expression was linked to
poor outcomes, particularly in liver hepatocellular carcinoma (LIHC). This protein's expression also
showcased significant relationships with diverse molecular and immune subtypes.
Additionally, a prognostic nomogram was devised, integrating SLC7A11 expression and clinical
variables. High SLC7A11 levels corresponded with cell growth and senescence pathways in various
cancers and with lipid and cholesterol metabolism in LIHC. Furthermore, potential therapeutic
compounds for LIHC with high SLC7A11 were identified. Real-time PCR (qPCR) and Western
blot were conducted to explore the expression of SLC7A11 in tumor tissues and cancer cell
lines.
Conclusion: In summation, this study emphasizes the prognostic and immunological importance
of SLC7A11, spotlighting its potential as a therapeutic target in LIHC.